I85PREP
⌘ K
PPB Pharmacist Pre-registration Exam study materials
PPB Pharmacist Pre-registration Exam study resources

PPB Pharmacist Pre-registration Exam practice questions

One question at a time. Build your PPB Pharmacist Pre-registration Exam understanding.

First 50 of 200 questions. Each one lists the choices, the correct answer, and an explanation. The checker at the top of this page saves progress in this browser when it is available.

Continue in the practice tool above to load more questions, 50 at a time.

Question 1Registration and Marketing Authorisation (MA)

Under the UK Human Medicines Regulations, which body is the competent authority that grants a UK marketing authorisation for a medicinal product?

  1. The National Institute for Health and Care Excellence
  2. The General Pharmaceutical Council
  3. The British Pharmacopoeia Commission
  4. The Medicines and Healthcare products Regulatory Agency Correct answer.

Explanation

The MHRA is the UK competent authority responsible for licensing medicines, including granting UK marketing authorisations and maintaining the product licence register. NICE advises on cost-effectiveness, the GPhC regulates pharmacy professionals, and the BP Commission sets pharmacopoeial standards, none of which grant MAs.

Question 2Registration and Marketing Authorisation (MA)

An application for a UK national marketing authorisation is submitted through which formal route before the licensing authority decides on approval?

  1. A mutual recognition procedure based on an existing EU authorisation
  2. A decentralised procedure coordinated by a reference member state
  3. A national application assessed directly by the MHRA Correct answer.
  4. A centralised procedure assessed by the European Medicines Agency

Explanation

A purely national UK application is submitted to and assessed by the MHRA directly, with no involvement of other member states. Decentralised and mutual recognition procedures are EU mechanisms, and the centralised procedure leads to an EU-wide authorisation rather than a UK national one.

Question 3Registration and Marketing Authorisation (MA)

Which document forms the core scientific assessment of quality, safety and efficacy submitted in a marketing authorisation application?

  1. The patient information leaflet
  2. The summary of product characteristics
  3. The common technical document dossier Correct answer.
  4. The risk management plan

Explanation

The common technical document (CTD) is the structured dossier containing the quality, non-clinical and clinical modules that assessors evaluate. The SmPC and PIL are product information documents derived from the approved data, and the risk management plan addresses pharmacovigilance activities.

Question 4Registration and Marketing Authorisation (MA)

A company wishes to market a product that is essentially similar to an existing authorised medicine, relying on the originator's safety and efficacy data after the data exclusivity period. Which type of application is this?

  1. A generic application Correct answer.
  2. A fixed-combination application
  3. A well-established use application
  4. A full application with a complete stand-alone dossier

Explanation

A generic application relies on the reference product's data once exclusivity has expired, and must demonstrate essential similarity and bioequivalence rather than repeat full safety and efficacy studies. Full applications require the complete dossier, and well-established use applications rely on published literature rather than a reference product.

Question 5Registration and Marketing Authorisation (MA)

What is the standard period of data exclusivity for a new active substance in a UK marketing authorisation before generic applicants may rely on the originator's data?

  1. Ten years from the date of first authorisation
  2. Eight years from the date of first authorisation Correct answer.
  3. Five years from the date of first authorisation
  4. Fifteen years from the date of first authorisation

Explanation

The standard data exclusivity period is eight years from first authorisation, after which a generic application may be submitted, with a further two years of market protection giving a total of ten years. Five and fifteen years do not reflect the standard framework.

Question 6Registration and Marketing Authorisation (MA)

Which section of the summary of product characteristics states the approved therapeutic indications for which the medicine may be prescribed?

  1. Section 5.1 Pharmacodynamic properties
  2. Section 4.8 Undesirable effects
  3. Section 4.1 Therapeutic indications Correct answer.
  4. Section 4.2 Posology and method of administration

Explanation

Section 4.1 of the SmPC lists the therapeutic indications that have been approved for the product. Posology appears in 4.2, undesirable effects in 4.8, and pharmacodynamic properties in 5.1.

Question 7Registration and Marketing Authorisation (MA)

A marketing authorisation holder wants to add a new therapeutic indication to an existing product. What must be obtained before the product can be promoted for that indication?

  1. A wholesale dealer's licence amendment
  2. An approved variation to the marketing authorisation Correct answer.
  3. A new patient information leaflet approved by the GPhC
  4. A clinical trial authorisation from the MHRA

Explanation

Adding an indication changes the terms of the marketing authorisation and therefore requires an approved variation covering the SmPC and related product information. A clinical trial authorisation permits research, not marketing, and the GPhC does not approve leaflets.

Question 8Registration and Marketing Authorisation (MA)

Which classification applies to a variation that has the potential to affect the quality, safety or efficacy of a medicine and requires assessment before implementation?

  1. Type II variation Correct answer.
  2. Type IA notification
  3. Type IB variation
  4. Type IAIN notification

Explanation

A Type II variation covers major changes with potential impact on quality, safety or efficacy and requires prior assessment and approval before implementation. Type IA and IAIN are minor changes notified after implementation, and Type IB covers moderate changes with a defined assessment window.

Question 9Registration and Marketing Authorisation (MA)

Which element is a mandatory component of the labelling of a prescription-only medicine on the outer carton?

  1. The name and address of the prescribing clinician
  2. The name of the marketing authorisation holder Correct answer.
  3. The retail price of the product
  4. The expiry date of the batch

Explanation

The name of the marketing authorisation holder is a required labelling particular for medicines, along with the product name, active substances, batch number and expiry date. Prescriber details and retail prices are not required on the manufacturer's carton.

Question 10Registration and Marketing Authorisation (MA)

A prescription-only medicine must display which warning on its packaging to indicate that it can only be supplied against a prescription?

  1. POM Correct answer.
  2. Keep out of the reach and sight of children
  3. For external use only
  4. Do not store above 25 degrees Celsius

Explanation

The letters POM must appear on the packaging of a prescription-only medicine to denote its legal classification. The other statements are storage or safety warnings that may appear but do not indicate the prescription-only status.

Question 11Registration and Marketing Authorisation (MA)

Which legal classification allows a medicine to be sold only from a registered pharmacy by or under the supervision of a pharmacist?

  1. Pharmacy medicine Correct answer.
  2. Controlled drug
  3. Prescription-only medicine
  4. General sale list

Explanation

A pharmacy (P) medicine may be sold only in a registered pharmacy by or under the supervision of a pharmacist. General sale list medicines may be sold more widely, prescription-only medicines require a prescription, and controlled drugs are subject to additional misuse controls.

Question 12Registration and Marketing Authorisation (MA)

An applicant seeks authorisation for a product intended for a serious debilitating condition where no satisfactory alternative exists. Which mechanism may allow earlier authorisation based on less comprehensive clinical data?

  1. Conditional marketing authorisation Correct answer.
  2. Traditional herbal registration
  3. Parallel import licence
  4. Homeopathic registration

Explanation

A conditional marketing authorisation may be granted for products addressing unmet medical needs based on less complete data, subject to specific obligations and annual reassessment. Herbal and homeopathic registrations apply to different product categories, and parallel import licences cover importing already-authorised products.

Question 13Registration and Marketing Authorisation (MA)

Which type of marketing authorisation is granted to a product that is essentially similar to an existing authorised product but where the applicant has generated its own complete dossier?

  1. Well-established use application
  2. Generic application
  3. Informed consent application
  4. Full stand-alone application Correct answer.

Explanation

A full stand-alone application contains the applicant's own complete quality, safety and efficacy data even where the product is similar to an existing one. A generic application relies on the reference product's data, and an informed consent application relies on the consent of an existing MAH.

Question 14Registration and Marketing Authorisation (MA)

A parallel import licence permits which activity in the UK?

  1. Wholesale distribution of any unlicensed medicine
  2. Manufacture of a new product from imported active substances
  3. Export of UK-authorised products to another market
  4. Import and sale of a product already authorised in another country that is essentially similar to a UK-authorised product Correct answer.

Explanation

A parallel import licence allows a product authorised in another country to be imported and sold in the UK where it is essentially similar to an existing UK-authorised product and meets the required conditions. It does not authorise manufacture or general distribution of unlicensed medicines.

Question 15Registration and Marketing Authorisation (MA)

Which document must be included in the packaging of every medicine to provide information to the patient in lay language?

  1. The periodic safety update report
  2. The patient information leaflet Correct answer.
  3. The risk management plan
  4. The summary of product characteristics

Explanation

The patient information leaflet accompanies the medicine and presents the approved information in lay language for the user. The SmPC is for healthcare professionals, while the risk management plan and periodic safety update report are regulatory pharmacovigilance documents.

Question 16Registration and Marketing Authorisation (MA)

Which principle underlies the requirement that the patient information leaflet must be legible, clear and easy to use?

  1. The principle of subsidiarity
  2. The precautionary principle
  3. The principle of informed use Correct answer.
  4. The principle of data integrity

Explanation

The leaflet requirement supports informed use, enabling patients to understand how to take the medicine safely and to make informed decisions. The precautionary principle concerns risk avoidance, data integrity concerns record accuracy, and subsidiarity concerns decision-making levels.

Question 17Registration and Marketing Authorisation (MA)

Before a marketing authorisation is granted, which assessment ensures the manufacturing site and processes comply with good manufacturing practice?

  1. A GMP inspection of the manufacturing site Correct answer.
  2. A pharmacovigilance system audit
  3. A clinical trial site audit
  4. A bioequivalence study

Explanation

A GMP inspection verifies that the manufacturing site and processes meet good manufacturing practice requirements before authorisation. Bioequivalence studies address comparative pharmacokinetics, while pharmacovigilance audits and clinical trial audits address different activities.

Question 18Registration and Marketing Authorisation (MA)

An applicant wants to rely on an existing marketing authorisation held by another company, with that company's written agreement. Which application type is this?

  1. Full application
  2. Informed consent application Correct answer.
  3. Generic application
  4. Conditional marketing authorisation

Explanation

An informed consent application allows an applicant to rely on an existing authorisation with the written consent of the existing holder. A generic application instead relies on the expiry of data exclusivity, and a full application requires the applicant's own complete data.

Question 19Registration and Marketing Authorisation (MA)

Which fee category is payable to the MHRA when a new marketing authorisation application is submitted for assessment?

  1. A wholesale distribution levy
  2. An application fee Correct answer.
  3. A capital fee
  4. A periodic inspection levy

Explanation

The MHRA charges an application fee for assessing a new marketing authorisation, calculated according to the type and complexity of the application. Capital fees relate to other regulatory activities, and levies relate to inspection or distribution activities.

Question 20Registration and Marketing Authorisation (MA)

What is the principal purpose of the summary of product characteristics for a healthcare professional?

  1. To provide a concise summary of the product's approved information to guide safe and effective use Correct answer.
  2. To set the retail price of the medicine
  3. To describe the manufacturer's internal quality control procedures
  4. To record adverse drug reactions reported by patients

Explanation

The SmPC summarises the approved information on indications, posology, contraindications, warnings and other key data for prescribers and dispensers. It is not a record of adverse reactions, a description of internal quality control, or a pricing document.

Question 21Registration and Marketing Authorisation (MA)

A product authorised in another EU member state is essentially similar to a UK-authorised product. Which mechanism allows it to be placed on the UK market without a full new application?

  1. A parallel import licence Correct answer.
  2. A traditional herbal registration
  3. A clinical trial authorisation
  4. A wholesale dealer's licence

Explanation

A parallel import licence permits the import and sale of an essentially similar product already authorised in another country, subject to conditions such as matching the UK product information. Clinical trial authorisations, wholesale dealer's licences and herbal registrations serve different purposes.

Question 22Registration and Marketing Authorisation (MA)

Which requirement must a traditional herbal medicinal product satisfy to obtain a traditional herbal registration?

  1. It must have undergone full clinical trials in the UK
  2. It must have been in medicinal use for at least 30 years, including 15 within the UK or EU Correct answer.
  3. It must be administered only by injection
  4. It must contain a controlled drug

Explanation

Traditional herbal registration requires evidence of at least 30 years of medicinal use, with at least 15 years within the UK or EU, demonstrating plausibility of traditional use. It does not require full clinical trials, and products containing controlled drugs or administered by injection are excluded.

Question 23Registration and Marketing Authorisation (MA)

Which body is responsible for issuing a wholesale dealer's licence in the UK?

  1. The Medicines and Healthcare products Regulatory Agency Correct answer.
  2. The General Pharmaceutical Council
  3. The British Pharmacopoeia Commission
  4. The National Institute for Health and Care Excellence

Explanation

The MHRA issues wholesale dealer's licences, which authorise the wholesale distribution of medicines. The GPhC registers pharmacy premises, NICE issues guidance, and the BP Commission sets standards.

Question 24Registration and Marketing Authorisation (MA)

A company wants to change the manufacturer of the active substance for an authorised product. This change is likely to be classified as which type of variation if it has potential to affect quality?

  1. Type IA notification
  2. Type II variation Correct answer.
  3. Type IB variation
  4. No variation is required

Explanation

A change of active substance manufacturer can affect quality and therefore generally requires a Type II variation with prior assessment and approval. Type IA and IB cover minor and moderate changes respectively, and some variation is always required for a change of this nature.

Question 25Registration and Marketing Authorisation (MA)

Which information is required on the label of a dispensed prescription-only medicine but not on the manufacturer's original carton?

  1. The batch number
  2. The expiry date
  3. The name of the patient and directions for use Correct answer.
  4. The name of the marketing authorisation holder

Explanation

The dispensed label must include the patient's name and the directions for use, which are specific to the individual supply. The MAH name, batch number and expiry date are required on the manufacturer's packaging.

Question 26Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Under the GPhC Standards for Registered Pharmacies, which individual is accountable for ensuring that pharmacy services are safe and effective and that the pharmacy team is properly managed?

  1. The pharmacy owner's nominated area manager
  2. The superintendent pharmacist or chief pharmacist Correct answer.
  3. The responsible pharmacist for each day of operation
  4. The most senior medicines counter assistant on duty

Explanation

The Standards for Registered Pharmacies place overall accountability for the safe and effective running of the pharmacy on the superintendent pharmacist or chief pharmacist, who must ensure governance, staffing and premises meet the standards. The responsible pharmacist is accountable for the safe running of the pharmacy during a specific period of absence but does not hold the overarching corporate accountability.

Question 27Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist wishes to record their continuing professional development in the GPhC system. Which format is required for each CPD entry?

  1. A reflective account structured around the four CPD stages of reflect, plan, act and evaluate Correct answer.
  2. A certificate of attendance for each educational event attended
  3. A log of hours spent on each learning activity signed by a supervisor
  4. A multiple-choice assessment completed at the end of each year

Explanation

The GPhC requires CPD records to be reflective and structured around the four stages: reflect, plan, act and evaluate. Attendance certificates or hour logs alone do not demonstrate the reflection and evaluation that the standards require.

Question 28Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which document must a registered pharmacy have available on the premises and produce on request to a GPhC inspector?

  1. The employer's staff holiday rota
  2. The current certificate of registration for the premises Correct answer.
  3. The wholesaler dealer licence for the pharmacy chain
  4. The lease agreement for the building

Explanation

A registered pharmacy must display or make available its premises registration certificate, and it must be produced to an inspector on request. Building leases, rotas and dealer licences are not the document required for inspection of premises registration.

Question 29Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist qualified in another country wants to register with the GPhC. Which route applies to a pharmacist whose qualifications are not automatically recognised?

  1. Automatic provisional registration for a twelve-month supervised period
  2. Registration as a pharmacy technician until a UK degree is completed
  3. Direct registration without further assessment if English is their first language
  4. Completion of the overseas pharmacists' assessment programme, including a written and oral assessment Correct answer.

Explanation

Pharmacists with non-recognised overseas qualifications must complete the overseas pharmacists' assessment programme, which includes written and oral assessments of competence, before they can apply for registration. Language alone or provisional registration does not substitute for this assessment.

Question 30Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

During a busy dispensary session the responsible pharmacist leaves the premises for a scheduled lunch break without arranging cover. Which standard is most directly breached?

  1. The requirement for staff to complete annual safeguarding training
  2. The requirement for the pharmacy to have a private consultation area
  3. The requirement that the pharmacy has a written patient safety incident procedure
  4. The requirement for the responsible pharmacist to be present and accountable during the pharmacy's operating hours Correct answer.

Explanation

The responsible pharmacist must be present and accountable for the safe running of the pharmacy during the period they are responsible for it, unless suitable arrangements are in place. Leaving without cover removes that accountability and breaches the presence requirement directly.

Question 31Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacy team is designing a system for recording and reviewing patient safety incidents. Which approach best meets the GPhC standards?

  1. Recording incidents only when a complaint is made by the patient or their representative
  2. Recording only incidents that resulted in patient harm and reporting them annually to the GPhC
  3. Recording all incidents including near misses, reviewing them to identify causes, and making changes to prevent recurrence Correct answer.
  4. Recording incidents in staff appraisals so that individual performance can be managed

Explanation

The standards require a culture of openness in which all patient safety incidents, including near misses, are recorded, reviewed and used to improve systems. The focus is on learning and system change rather than blame or reporting only harm events.

Question 32Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which statement best describes the purpose of the GPhC's revalidation process for pharmacists?

  1. It replaces the requirement to maintain a CPD record
  2. It confirms that pharmacists remain fit to practise by demonstrating continued professional development and reflective practice Correct answer.
  3. It is a one-off assessment taken only at the point of initial registration
  4. It is an examination that must be passed every year to retain registration

Explanation

Revalidation is an ongoing process confirming continued fitness to practise, based on recorded CPD and reflective accounts rather than a single examination. It complements, rather than replaces, the CPD requirement.

Question 33Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist is asked to supervise a foundation trainee. Which activity is most appropriate for the pharmacist to delegate to the trainee under supervision?

  1. Authorising a repeat prescription request without pharmacist review
  2. Signing off the trainee's own final competence declaration
  3. Counselling a patient on inhaler technique with the pharmacist observing and providing feedback Correct answer.
  4. Making the final accuracy check on a controlled drug dispensed for a hospice

Explanation

Supervised learning activities allow trainees to develop skills while the registered pharmacist retains accountability and observes performance. Tasks requiring professional judgement, final accuracy checking or self-declaration cannot be delegated to the trainee.

Question 34Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which of the following best describes the role of a designated prescribing practitioner in the context of pharmacist independent prescribing training?

  1. A registered practitioner who supervises and assesses the pharmacist's prescribing competence in practice Correct answer.
  2. A person who writes the prescribing examination questions for the training provider
  3. A pharmaceutical industry representative who supplies prescribing materials
  4. A GPhC inspector who audits the prescribing course provider

Explanation

The designated prescribing practitioner is a registered healthcare professional responsible for supervising and assessing the trainee prescriber's competence in the practice setting. This role is distinct from course design, inspection or industry supply.

Question 35Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacy owner wants to open a new branch and must apply to the GPhC. Which condition must be satisfied before the premises can be registered?

  1. The premises must be inspected and confirmed to meet standards for facilities, security and record storage Correct answer.
  2. The pharmacy must hold a wholesale dealer licence
  3. The pharmacy must already employ at least two pharmacists
  4. The premises must be located within one mile of a GP surgery

Explanation

Registration of premises is granted once the premises have been inspected and found to meet the standards for suitable facilities, security and record storage. There is no minimum pharmacist number, proximity to a GP surgery or wholesale licence requirement for retail registration.

Question 36Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which activity would breach the GPhC standards on maintaining professional boundaries with patients?

  1. Providing a patient with written information about their medicine
  2. Offering a patient a chaperone during a sensitive consultation
  3. Borrowing money from a patient you have recently dispensed medicines to Correct answer.
  4. Accepting a small box of chocolates as a thank-you gift at Christmas

Explanation

Entering into a financial relationship such as borrowing money from a patient crosses professional boundaries and exploits the power imbalance in the professional relationship. Accepting modest gifts, offering chaperones and providing information are acceptable within boundaries.

Question 37Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist is asked to provide evidence of their CPD during a GPhC inspection. Which record is most likely to demonstrate compliance with the CPD standards?

  1. A reflective record showing how a learning need was identified, addressed and evaluated Correct answer.
  2. A list of journal articles read over the past year with no commentary
  3. A spreadsheet counting the number of hours spent on each training course
  4. A certificate from a one-day conference attended two years ago

Explanation

Compliance is demonstrated by reflective records that show the cycle of identifying a need, planning and undertaking learning, and evaluating its impact on practice. Lists, certificates and hour counts alone do not demonstrate this reflective process.

Question 38Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which statement about the GPhC's threshold criteria for fitness to practise is correct?

  1. They set the minimum A-level grades required for entry to a pharmacy degree
  2. They list the medicines that a pharmacist may supply without a prescription
  3. They define the minimum standards of conduct and competence below which a pharmacist's fitness to practise may be impaired Correct answer.
  4. They specify the maximum number of hours a pharmacist may work each week

Explanation

The threshold criteria describe the standards of conduct, performance and health below which a registrant's fitness to practise may be considered impaired. They are not entry requirements, working-time limits or a medicines classification list.

Question 39Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist wants to return to practice after a five-year career break during which they did not practise. Which step is most appropriate before resuming patient-facing work?

  1. Complete a return-to-practice programme or equivalent updating, including a period of supervised practice where required Correct answer.
  2. Register immediately and begin work without any further preparation
  3. Rely on their original degree certificate as evidence of current competence
  4. Ask a colleague to sign a declaration confirming their competence

Explanation

Pharmacists returning after a significant break must update their knowledge and skills, typically through a return-to-practice programme with supervised practice where required, before resuming patient-facing work. A degree certificate or a colleague's declaration does not evidence current competence.

Question 40Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which of the following best describes the purpose of the GPhC's standards for pharmacy professionals regarding raising concerns?

  1. To support professionals in speaking up about risks to patient safety, including through internal and external routes Correct answer.
  2. To require concerns to be kept confidential from the regulator in all circumstances
  3. To require pharmacists to report every minor error to the police
  4. To prevent pharmacists from discussing concerns with colleagues outside their employer

Explanation

The standards require pharmacy professionals to raise concerns promptly where they believe patient safety or public confidence is at risk, using appropriate internal and, where necessary, external routes. The aim is protection of patients, not concealment or police reporting of minor matters.

Question 41Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist is asked to complete a mandatory training module on safeguarding children. Which statement best explains why this training is required?

  1. It ensures staff can recognise and respond appropriately to signs of abuse or neglect in patients Correct answer.
  2. It is required only for pharmacists who work in hospitals
  3. It is an optional activity that counts towards CPD only
  4. It replaces the need for a local safeguarding policy

Explanation

Safeguarding training equips pharmacy staff to recognise signs of abuse or neglect and to respond through the correct local procedures. It applies across settings and complements, rather than replaces, local policies.

Question 42Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which action best demonstrates that a pharmacist is meeting the GPhC standard on working in partnership with patients?

  1. Explaining treatment options and checking the patient's understanding before agreeing a plan Correct answer.
  2. Referring every patient to the prescriber for all decisions
  3. Choosing the medicine for the patient without discussing options
  4. Providing a leaflet without any discussion

Explanation

Working in partnership involves sharing information, exploring the patient's views and agreeing a plan together, then checking understanding. Making decisions unilaterally, providing information without discussion or routinely redirecting all decisions does not demonstrate partnership.

Question 43Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacy technician employed at a registered pharmacy wishes to become a registered pharmacist. Which statement best describes the training route?

  1. They can register as a pharmacist after completing a short conversion course of one month
  2. They can transfer directly from the technician register to the pharmacist register after five years
  3. They must complete a GPhC-accredited Master of Pharmacy degree or equivalent and meet all registration requirements Correct answer.
  4. They are exempt from the pre-registration requirements because of their technician experience

Explanation

Becoming a pharmacist requires completion of a GPhC-accredited MPharm degree or equivalent, together with the other registration requirements such as pre-registration training and assessment. Technician experience does not provide an automatic transfer or exemption.

Question 44Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which of the following is the most appropriate way for a pharmacist to maintain competence in a specialist area such as oncology pharmacy?

  1. Rely solely on experience gained in the first year after qualification
  2. Attend a single conference and consider competence maintained permanently
  3. Engage in ongoing CPD, peer review and relevant specialist training throughout their career Correct answer.
  4. Assume competence because the employer has not raised concerns

Explanation

Maintaining competence is a continuous professional obligation requiring ongoing CPD, peer review and relevant training. Experience from early in a career, a single event or the absence of employer concerns does not demonstrate current competence.

Question 45Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist discovers that a colleague has been practising while their registration has lapsed. What is the most appropriate immediate action?

  1. Raise the concern promptly with the employer and, where appropriate, the regulator so that patients are protected Correct answer.
  2. Wait until the next annual appraisal to mention it
  3. Ignore the matter because it is the employer's responsibility
  4. Discuss it only with the colleague and take no further action

Explanation

Practising without current registration is a serious risk to patient safety and public confidence, so the concern must be raised promptly with the employer and, where appropriate, the regulator. Ignoring it, private discussion only or delay leaves patients unprotected.

Question 46Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which statement best describes the GPhC requirement for pharmacists regarding indemnity insurance?

  1. Indemnity insurance is optional for all pharmacists in every setting
  2. Indemnity is required only for pharmacists working in community pharmacy
  3. Pharmacists must hold appropriate indemnity arrangements that cover their scope of practice Correct answer.
  4. Indemnity is provided automatically by the GPhC to all registrants

Explanation

Pharmacists must ensure they have appropriate indemnity arrangements in place covering the full scope of their practice. The requirement is not limited to community pharmacy and cover is not provided automatically by the regulator.

Question 47Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist is designing a personal development plan at the start of the year. Which element is essential for the plan to meet CPD standards?

  1. A copy of the employer's business plan
  2. A list of all training courses available in the region
  3. Specific learning needs linked to the pharmacist's practice and intended outcomes Correct answer.
  4. A record of the pharmacist's annual salary and grade

Explanation

A meaningful development plan identifies specific learning needs relevant to the pharmacist's practice and states the intended outcomes and how they will be evaluated. Lists of available courses, salary details or business plans do not constitute a personal development plan.

Question 48Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

Which of the following best reflects the GPhC standard on leadership within pharmacy teams?

  1. Leadership responsibilities apply only to superintendents and not to other pharmacists
  2. Leaders should ensure staff are afraid to report errors so standards are maintained
  3. Pharmacists in leadership roles should create a culture of openness, learning and accountability Correct answer.
  4. Leadership means avoiding any change to established routines

Explanation

The standards expect pharmacists in leadership roles to foster openness, learning and accountability so that risks are identified and addressed. Fear-based cultures, restricting leadership to superintendents or resisting all change are inconsistent with these expectations.

Question 49Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist is asked to give a teaching session to colleagues on the GPhC standards. Which approach best demonstrates understanding of the standards' structure?

  1. Presenting the standards as a list of rules with penalties for each breach
  2. Describing the standards as optional guidance that employers may adopt
  3. Explaining that the standards describe principles of good practice that professionals apply using judgement in context Correct answer.
  4. Stating that the standards apply only to newly qualified pharmacists

Explanation

The standards set out principles of good practice that registrants must apply with professional judgement in their particular context, rather than a rigid penalty schedule. They apply to all registrants and are not optional.

Question 50Licensing, Good Pharmacy Practice, Training & Continuing Professional Development (CPD)

A pharmacist notices that a training programme for support staff omits any content on recognising counterfeit medicines. Which action best reflects the pharmacist's professional responsibilities?

  1. Wait until the next inspection and let the inspector identify the gap
  2. Ignore the omission because support staff do not handle medicines
  3. Raise the gap with the training provider or employer and propose additional content to address the risk Correct answer.
  4. Ask support staff to research the topic independently without any formal training

Explanation

Pharmacists have a responsibility to ensure staff are competent for the tasks they perform, so gaps in training that create patient risk should be raised and addressed proactively. Ignoring the gap, waiting for inspection or leaving staff to self-teach does not meet this responsibility.